Daily biotech intelligence: FDA actions, drug recalls, and recent research.
Unknown — Approved Sponsor: BAXTER HLTHCARE CORP · Application type: ORIG · Date: 20260415 · Priority: STANDARD
BUPRENORPHINE AND NALOXONE — Approved Sponsor: DR REDDYS LABS SA · Application type: SUPPL · Date: 20181031
DATSCAN (IOFLUPANE I-123) — Approved Sponsor: GE HLTHCARE INC · Application type: SUPPL · Date: 20260415 · Priority: STANDARD
BOSENTAN — Approved Sponsor: ZYDUS PHARMS · Application type: SUPPL · Date: 20260414 · Priority: STANDARD
Unknown — Tentative Approval Sponsor: QILU PHARM HAINAN · Application type: ORIG · Date: 20260415 · Priority: STANDARD
ITOVEBI (INAVOLISIB) — Approved Sponsor: GENENTECH INC · Application type: SUPPL · Date: 20260415 · Priority: STANDARD
MILNACIPRAN HYDROCHLORIDE — Approved Sponsor: BRECKENRIDGE · Application type: ORIG · Date: 20160127 · Priority: STANDARD
DANZITEN (NILOTINIB) — Approved Sponsor: AZURITY · Application type: ORIG · Date: 20241107 · Priority: STANDARD
CHLORPROMAZINE HYDROCHLORIDE — Approved Sponsor: SAPTALIS PHARMS · Application type: SUPPL · Date: 19900216
GLYCEROL PHENYLBUTYRATE — Approved Sponsor: TEVA PHARMS INC · Application type: ORIG · Date: 20260415 · Priority: STANDARD
Fagron Compounding Services [Class II] — 20260415 Product: Vancomycin HCI, 1.5 grams added to 250 mL, 0.9% Sodium Chloride Injection USP, Fagron Sterile Servic Reason: Lack of Assurance of Sterility; blue Break-Off-Part could detach from the administration port
Fresenius Kabi USA, LLC [Class II] — 20260415 Product: 0.9% Sodium Chloride Injection, USP, (2,250 mg per 250 mL) (9 mg per mL) 250 mL in a 250 mL freeflex Reason: Lack of Assurance of Sterility
Fresenius Kabi USA, LLC [Class II] — 20260415 Product: 0.45% Sodium Chloride Injection, USP, 1.125 grams per 250 mL (4.5 mg per mL), 250 mL in a 250 mL fre Reason: Lack of Assurance of Sterility
Teva Pharmaceuticals USA, Inc [Class II] — 20260415 Product: Clonidine Transdermal System, USP, 0.2 mg/day, supplied in cartons of 4 Systems and 4 Adhesive Cover Reason: CGMP Deviations: use of an unapproved raw material
Fresenius Kabi USA, LLC [Class II] — 20260415 Product: 0.9% Sodium Chloride Injection, USP 900 mg per 100 mL (9 mg per mL) 500 mL in a Single Dose freeflex Reason: Lack of Assurance of Sterility
Shaden Alshammari, Kevin Wen, Abrar Zainal · 2026-04-20 · cs.AI · cs.DL
Mathematical problem solving remains a challenging test of reasoning for large language and multimodal models, yet existing benchmarks are limited in size, language coverage, and task diversity. We introduce MathNet, a high-quality, large-scale, multimodal, and multilingual dataset of Olympiad-level math problems together with a benchmark for evalu
Liubomyr Horbatko · 2026-04-20 · cs.LG · cs.AI
Modern sequence models are dominated by Transformers, where self-attention mixes information from the visible context in an input-dependent way. However, when retrieval is not sharp and attention remains diffuse over an effective support $S_{\mathrm{eff}}(t)$, the influence of any individual token is diluted, typically scaling as $O(1/S_{\mathrm{ef
Yunke Ao, Le Chen, Bruce D. Lee · 2026-04-20 · cs.LG · cs.AI
Proximal Policy Optimization (PPO) has become the predominant algorithm for on-policy reinforcement learning due to its scalability and empirical robustness across domains. However, there is a significant disconnect between the underlying foundations of trust region methods and the heuristic clipped objective used in PPO. In this paper, we bridge t
Salman Rahman, Jingyan Shen, Anna Mordvina · 2026-04-20 · cs.LG · cs.AI
Large language models have achieved significant reasoning improvements through reinforcement learning with verifiable rewards (RLVR). Yet as model capabilities grow, constructing high-quality reward signals becomes increasingly difficult, making it essential to understand when RLVR can succeed under weaker forms of supervision. We conduct a systema
A. Sophia Koepke, Daniil Zverev, Shiry Ginosar · 2026-04-20 · cs.CV · cs.AI
The Platonic Representation Hypothesis suggests that neural networks trained on different modalities (e.g., text and images) align and eventually converge toward the same representation of reality. If true, this has significant implications for whether modality choice matters at all. We show that the experimental evidence for this hypothesis is fra
Andrew Zhang, Tong Ding, Sophia J. Wagner · 2026-04-20 · cs.LG · cs.AI
Modern medicine generates vast multimodal data across siloed systems, yet no existing model integrates the full breadth and temporal depth of the clinical record into a unified patient representation. We introduce Apollo, a multimodal temporal foundation model trained and evaluated on over three decades of longitudinal hospital records from a major
Maria-Eleni Sfyraki, Jun-Kun Wang · 2026-04-20 · stat.ML · cs.LG
In this work, we revisit the problem of active sequential prediction-powered mean estimation, where at each round one must decide the query probability of the ground-truth label upon observing the covariates of a sample. Furthermore, if the label is not queried, the prediction from a machine learning model is used instead. Prior work proposed an el
Manan Gupta, Dhruv Kumar · 2026-04-20 · cs.LG · cs.AI
Large language models frequently commit unrecoverable reasoning errors mid-generation: once a wrong step is taken, subsequent tokens compound the mistake rather than correct it. We introduce $\textbf{Latent Phase-Shift Rollback}$ (LPSR): at each generation step, we monitor the residual stream at a critical layer lcrit, detect abrupt directional rev
STAT+: BioAge says experimental pill aimed at reducing heart risks significantly reduced inflammation (STAT News) BioAge Labs said its investigational pill for cardiovascular risk prevention significantly reduced inflammation in an early study.
STAT+: Tortugas Neuroscience launches with hopes to develop drugs for brain disorders, other conditions (STAT News) Tortugas Neuroscience launched Tuesday with plans to develop drugs licensed from Chinese drugmaker Jiangsu Hansoh and Japanese pharmaceutical Eisai.
Opinion: What happens when a chief executive loses executive functions? (STAT News) When a CEO develops acquired executive dysfunction yet remains in their role, the challenges are significant.
Opinion: The U.S. health care system is built around looking backward (STAT News) A reconstruction layer has fallen on medicine. It asks: Was the original decision justified?
STAT+: At AACR, a provocative use of CAR-T, Merck’s new thing and cancer’s geography problem (STAT News) At AACR, a bold use of CAR-T raises hopes and provocative questions about its use in smoldering multiple myeloma.
STAT+: Former banker brought on to revitalize Pfizer’s strategy departs his post (STAT News) Andrew Baum, a former Citi analyst, has left his role as Pfizer's executive vice president and chief strategy and innovation officer.
STAT+: In early trial, CAR-T results raise hope of preventing multiple myeloma in high-risk patients (STAT News) A CAR-T trial shows promise in preventing smoldering multiple myeloma from becoming the real thing.
STAT+: Trump order to advance psychedelic treatments generates excitement — and worries (STAT News) President Trump’s executive order on was largely applauded by advocates. But some also quietly worried the White House’s role risks politicizing their field and undermining its credibility.
Opinion: The contradiction at the heart of Republicans’ embrace of psychedelics (STAT News) “The research is clear about one thing: Recovery is not primarily a pharmacological event,” write Dimitri Mugianis and Ross Ellenhorn.
STAT+: Eli Lilly’s $3.25 billion acquisition of Kelonia Therapeutics caps startup’s tortuous ride (STAT News) Kelonia Therapeutics, a small biotech company, long struggled to stay afloat. Now it's been acquired by Eli Lilly for $3.25 billion.
Serif, Flagship’s latest biotech, aims to make a new kind of genetic medicine (BioPharma Dive) The startup is developing “modified DNA” therapies it claims can combine the strengths of multiple approaches, from messenger RNA to gene therapy.
Trump executive order lifts psychedelics biotechs (BioPharma Dive) Meant to speed research and access to psychedelics for mental health conditions, the order is the latest in a series of developments that, to Wall Street, make psychedelics a more “investable space.”
This briefing is compiled automatically from FDA public APIs (openFDA), arXiv, and industry RSS feeds (STAT News, Fierce Biotech, BioPharma Dive, Nature, Science News). Not investment advice. Verify all data before making any decisions.